Liminatus Pharma (LIMN) Net Cash Flow (2024 - 2026)
Liminatus Pharma (LIMN) posted Net Cash Flow of $1.6 million for Q1 2026, up 505.85% sequentially from -$386847.0 in Q4 2025, and up 7438.94% YoY from $20825.5 in Q1 2025.
Liminatus Pharma (LIMN) Net Cash Flow (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Net Cash Flow for 3 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 7438.94% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 269.72% YoY) and the FY2025 annual result came in at $281336.0, up 174.41% from the prior year.
- Net Cash Flow advanced to $1.6 million in Q1 2026 per LIMN's latest filing, from -$386847.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $1.6 million in Q1 2026 and troughed at -$1.1 million in Q2 2024.
- A 3-year average of $96161.1 and a median of -$6026.5 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow sank 4864.54% in 2025, then surged 7438.94% in 2026.
- Over 3 years, Net Cash Flow stood at $9340.0 in 2024, then slumped by 4241.83% to -$386847.0 in 2025, then soared by 505.85% to $1.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $1.6 million, -$386847.0, and -$613720.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.57 Mn |
| Mar 31, 2026 | 1.57 Mn |
| Dec 31, 2025 | -386,847.00 |
| Dec 31, 2025 | -386,847.00 |
| Sep 30, 2025 | -613,720.00 |
| Sep 30, 2025 | -613,720.00 |
| Jun 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | -21,393.00 |
| Mar 31, 2025 | -21,393.00 |
| Dec 31, 2024 | 9,340.00 |
| Dec 31, 2024 | 9,340.00 |
| Sep 30, 2024 | 12,881.00 |
| Sep 30, 2024 | 12,881.00 |
| Jun 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -1.10 Mn |